Eylea 2 MG/0.05 ML syringe 0.05ML
Ended Awarded Last action
- Contract number
- SPE2DR26FMED8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $28,674
Award facts
- Contract value 100% obligated
- $28,674.24 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency has awarded a $28.7K firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for EYLEA 2 mg/0.05 mL syringes. This delivery order, issued on January 5, 2026, with an ultimate completion date of January 27, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors supplying the Department of Defense's pharmaceutical and medical consumables needs globally.
DMS Pharmaceutical Group, registered in the System for Award Management since 2001, serves as a critical supplier within the federal pharmaceutical supply chain, with its PPV-G GEN V contract ceiling valued at $500M and extending through December 2036. The contractor's product portfolio encompasses a comprehensive range of therapeutics including branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals. This delivery order for EYLEA, an ophthalmologic therapeutic agent, exemplifies the company's role in fulfilling the specialized and diverse pharmaceutical requirements of military healthcare facilities and Department of Defense medical operations worldwide.
Quick answers
Who was awarded contract SPE2DR26FMED8?
SPE2DR26FMED8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 5, 2026.
How much is contract SPE2DR26FMED8 worth?
The government has obligated $28,674 on SPE2DR26FMED8.
Is contract SPE2DR26FMED8 an order under another contract?
Yes. SPE2DR26FMED8 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMED8 competed?
The extent of competition for SPE2DR26FMED8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award